Formulation of novel sustained release rifampicin-loaded solid lipid microparticles based on structured lipid matrices from Moringa oleifera

Objectives: To formulate sustained release rifampicin-loaded solid lipid microparticles (SLMs) using structured lipid matrices based on Moringa oil (MO) and Phospholipon 90G (P90G). Methods: Rifampicin-loaded and unloaded SLMs were formulated by melt homogenization and characterized in terms of part...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutical development and technology 2015-01, Vol.20 (5), p.546-554
Main Authors: Onyishi, Ikechukwu V., Chime, Salome A., Ogudiegwu, Echezona O.
Format: Article
Language:English
Subjects:
Animals
Antibiotics, Antitubercular - administration & dosage
Antibiotics, Antitubercular - pharmacokinetics
Antibiotics, Antitubercular - pharmacology
Delayed-Action Preparations - chemistry
In vivo release
lipid absorption
Lipids - chemistry
Male
Moringa oil
Moringa oleifera - chemistry
Particle Size
Plant Oils - chemistry
Rats, Wistar
Rifampin - administration & dosage
Rifampin - pharmacokinetics
Rifampin - pharmacology
tuberculosis
Tuberculosis - drug therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives: To formulate sustained release rifampicin-loaded solid lipid microparticles (SLMs) using structured lipid matrices based on Moringa oil (MO) and Phospholipon 90G (P90G). Methods: Rifampicin-loaded and unloaded SLMs were formulated by melt homogenization and characterized in terms of particle morphology and size, percentage drug content (PDC), pH stability, stability in simulated gastric fluid (SGF, pH 1.2), minimum inhibitory concentration (MIC) and in vitro release. In vivo release was studied in Wistar rats. Results: Rifampicin-loaded SLMs had particle size range of 32.50 ± 2.10 to 34.0 ± 8.40 μm, highest PDC of 87.6% and showed stable pH. SLMs had good sustained release properties with about 77.1% release at 12 h in phosphate buffer (pH 6.8) and 80.3% drug release at 12 h in simulated intestinal fluid (SIF, pH 7.4). SLMs exhibited 48.51% degradation of rifampicin in SGF at 3 h, while rifampicin pure sample had 95.5% degradation. Formulations exhibited MIC range of 0.781 to 1.562, 31.25 to 62.5 and 6.25 to 12.5 μg/ml against Salmonella typhi, Escherichia coli, and Bacillus subtilis respectively and had higher in vivo absorption than the reference rifampicin (p 
ISSN:1083-7450
1097-9867
DOI:10.3109/10837450.2014.898654